* Cerevel Therapeutics Holdings Inc is expected to show no change in quarterly revenue when it reports results on May 1 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Cerevel Therapeutics Holdings Inc is for a loss of 61 cents per share.
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Cerevel Therapeutics Holdings Inc is $45.00, above its last closing price of $42.47.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.59 -0.59 -0.76 Missed -27.8
Sep. 30 0001 -0.64 -0.63 -0.61 Beat 3.5
Jun. 30 2023 -0.64 -0.65 -0.63 Beat 2.9
Mar. 31 2023 -0.69 -0.67 -0.67 Met 0.6
Dec. -0.64 -0.64 -0.59 Beat 8
31 2022
Sep. 30 2022 -0.62 -0.62 -0.66 Missed -7.1
Jun. 30 2022 -0.50 -0.48 -0.62 Missed -30.3
Mar. 31 2022 -0.43 -0.42 -0.46 Missed -8.2
This summary was machine generated April 29 at 14:57 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments